Cytek Biosciences (CTKB) Share-based Compensation (2020 - 2025)

Cytek Biosciences' Share-based Compensation history runs 6 years deep, the most recent figure standing at $5.5 million for Q4 2025.

• Quarterly Share-based Compensation rose 412.23% year-over-year to $5.5 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $18.0 million (up 384.48% YoY) and the FY2025 annual result came in at $24.6 million, up 805.19% from the prior year.
• Share-based Compensation was $5.5 million for Q4 2025 at Cytek Biosciences, down from $5.6 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $22.0 million in Q4 2023 and bottomed at -$12.1 million in Q4 2022.
• A 5-year average of $2.8 million and a median of $3.9 million in 2022 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2021 — Share-based Compensation jumped 1009.96% — and 2022, when it slumped 503.26%.
• Cytek Biosciences' Share-based Compensation stood at $3.0 million in 2021, then slumped by 503.26% to -$12.1 million in 2022, then surged by 281.76% to $22.0 million in 2023, then tumbled by 95.11% to $1.1 million in 2024, then jumped by 412.23% to $5.5 million in 2025.
• Business Quant data shows CTKB's Share-based Compensation at $5.5 million in Q4 2025, $5.6 million in Q3 2025, and $6.8 million in Q2 2025.